Asymmetric dimethylarginine (ADMA) has a role in regulating systemic vascular tone in young healthy subjects: The cardiovascular risk in young Finns study

American Journal of Hypertension

Volumn 21, Issue 8, 2008, Pages 873-878

  Päivä, Hannu ^a   Kähönen, Mika ^b   Lehtimäki, Terho ^a,b   Raitakari, Olli T ^c   Jula, Antti ^d   Viikari, Jorma ^c   Alfthan, Georg ^d   Juonala, Markus ^c   Laaksonen, Reijo ^a,e   Hutri Kähönen, Nina ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; EVALUATION; FEEDBACK SYSTEM; FOLLOW UP; HEART INDEX; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PULSE WAVE; STATISTICAL MODEL; SYSTEMIC VASCULAR RESISTANCE;

ADULT; ARGININE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; FINLAND; HUMANS; KIDNEY; LIPIDS; MALE; NITRIC OXIDE; RISK FACTORS; VASCULAR RESISTANCE; VASOCONSTRICTION; YOUNG ADULT;

EID: 47749134827     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.215     Document Type: Article

References (30)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
2. Leiper J, Vallance P. Biological significance of endogenous methylargines that inhibit nitric oxide synthase. Cardiovasc Res 1999; 43:542-548.
3. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor, a novel marker of atherosclerosis. Circulation 1999; 99:1141-1146.
4. Shepherd JT. Franz Volhard Lecture. Increased systemic vascular resistance and primary hypertension: the expanding complexity. J Hypertens Suppl 1990; 8:S15-S27.
5. Lehmann ED, Hopkins KD, Rawesh A, Joseph RC, Kongola K, Coppack SW, Gosling RG. Relation between number of cardiovascular risk factors/events and noninvasive Doppler ultrasound assessments of aortic compliance. Hypertension 1998; 32:565-569.
6. Amar J, Ruidavets JB, Chamontin B, Drouet L, Ferrieres J. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001; 19:381-387.
7. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Böger RH, Bode-Böger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Frölich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33:652-658.
8. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23:1455-1459.
9. Päivä H, Laakso J, Kähönen M, Turjanmaa V, Kööbi T, Majahalme S, Lehtimäki T, Ruokonen I, Laaksonen R. Asymmetric dimethylarginine and hemodynamic regulation in middle aged men. Metabolism 2006; 55:771-777.
10. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT 1-receptor blockade reduce the levels of asymmetrical N(g), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15:590-593.
11. Päivä H, Lehtimäki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, Pasternack A, Laaksonen R. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52:303-307.
12. Hemminki V, Laakso J, Kähönen M, Turjanmaa V, Uusitalo H, Lehtimäki T, Ruokonen I, Laaksonen R, Huhtala H, Päivä H. Plasma asymmetric dimethylarginine (ADMA) and retinal vessel diameters in middle-aged men. Metabolism 2007; 56:1305-1310.
13. Juonala M, Viikari JSA, Alfthan G, Marniemi J, Kähönen M, Taittonen L, Laitinen T, Raitakari OT. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the Cardiovascular Risk in Young Finns Study. Circulation 2007; 116:1367-1373.
14. Åkerblom HK, Viikari J, Uhari M, Räsänen L, Byckling T, Louhivuori K, Pesonen E, Suoninen P, Pietikäinen M, Lähde PL. Atherosclerosis precursors in Finnish children and adolescents. I. General description of the cross-sectional study of 1980, and an account of the children's and families' state of health. Acta Paediatr Scand Suppl 1985; 318:49-63.
15. Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, Järvisalo MJ, Uhari M, Jokinen E, Rönnemaa T, Åkerblom HK, Viikari JS. Cardiovascular risk factors in childhood as and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290:2277-2283.
16. Chobanian AV, Bakris GL, Black HR, Crushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-2572.
17. Imholz BP, Settels JJ, van der Meiracker AH, Wesseling KH, Wieling W. Non-invasive continuous finger blood pressure measurement during orthostatic stress compared to intra-arterial pressure. Cardiovasc Res 1990;24:214-221.
18. Kööbi T, Kaukinen S, Ahola T, Turjanmaa V. Non-invasive measurement of cardiac output: whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods. Intensive Care Med 1997; 23:1132-1137.
19. Tishchenko MI. Estimation of the stroke volume by integral rheogram of the human body. Sechenov Physiol 1973; 59:1216-1224.
20. Kööbi T, Kähönen M, Iivanainen T, Turjanmaa V. Simultaneous non-invasive assessment of arterial stiffness and haemodynamics - a validation study. Clin Physiol Funct Imaging 2003; 23:31-36.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
22. Teerlink T, Nijveldt RJ, de JOng S, van Leeuwen PAM. Determination of arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303: 131-137.
23. Shin T, Hideki F, Kei K, Takeshi H, Satoshi N, Aki H, Hiromi R, Toshio O, Yuhei K. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004; 17:802-808.
24. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109:172-177.
25. Päivä H, Laakso J, Laine H, Laaksonen R, Knuuti J, Raitakari OT. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 2002; 40:1241-1247.
26. Päivä H, Lehtimäki T, Laakso J, Ruokonen I, Tervonen R, Metso S, Nikkilä M, Wuolijoki E, Laaksonen R. Dietary composition as a determinant of plasma asymmetric dimethylarginine (ADMA) in subjects with mild hypercholesterolemia. Metabolism 2004; 53:1072-1075.
27. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
28. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM. ADMA increased arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37:2024-2029.
29. Weber T, Maas R, Auer J, Lamm G, Lassing E, Rammer M, O'Rourke MF, Böger RH, Eber B. Arterial wave reflections and determinants of endothelial function a hypothesis based on peripheral mode of action. Am J Hypertens 2007; 20:256-262.
30. Kielstein JT, Salpeter SR, Bode-Böger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function: meta-analysis. Nephrol Dial Transplant 2006; 21:2446-2451.